MDR1 gene expression in NOD/SCID repopulating cells after retroviral gene transfer under clinically relevant conditions

Molecular Therapy

Volumn 2, Issue 6, 2000, Pages 609-618

  Schilz, A J ^a   Schiedlmeier, B ^b   Kuhlcke K ^a   Fruehauf, S ^c   Lindemann, C ^a   Zeller, W J ^b   Grez, M ^d   Fauser, A A ^a,e   Baum, C ^f,g   Eckert, H G ^a  

^a BIONTECH AG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^e Oncology and BMT Hospital   (Germany)

^f LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

CD34+ cells; Gene therapy; MDR1; Mobilized peripheral blood; NOD SCID; Retroviral gene transfer

Indexed keywords

ALOCASIA MACRORRHIZOS; GIBBON APE LEUKEMIA VIRUS; HYLOBATES SP.;

CD34 ANTIGEN; GLYCOPROTEIN P; PRIMER DNA;

ANIMAL; ARTICLE; CELL DIVISION; CULTURE MEDIUM; CYTOLOGY; FEMALE; GENE EXPRESSION; GENE TRANSFER; GENETICS; HEMATOPOIETIC STEM CELL; IMMUNOLOGY; MOUSE; MOUSE MUTANT; NONOBESE DIABETIC MOUSE; NUCLEOTIDE SEQUENCE; RETROVIRUS;

ANIMALS; ANTIGENS, CD34; BASE SEQUENCE; CELL DIVISION; CULTURE MEDIA, SERUM-FREE; DNA PRIMERS; FEMALE; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; HEMATOPOIETIC STEM CELLS; MICE; MICE, INBRED NOD; MICE, SCID; P-GLYCOPROTEIN; RETROVIRIDAE;

EID: 0034571820     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2000.0216     Document Type: Article

References (77)

1. Miller, D. G., Adam, M. A., and Miller, A. D. (1990). Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol. Cell. Biol. 10: 4239-4242.
2. Lewis, P. F., and Emerman, M. (1994). Passage through mitosis is required for oncoretroviruses but not for human immunodeficiency virus. J. Virol. 68: 510-516.
3. To, L. B., Haylock, D. N., Simmons, P. J., and Juttner, C. A. (1997). The biology and clinical uses of blood stem cells. Blood 89: 2233-2258.
4. Beyer, J., et al. (1995). Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: A randomized comparison. J. Clin. Oncol. 13: 1328-1335.
5. Brenner, M. K., et al. (1993). Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet 342: 1134-1137.
6. + cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow transplantation in CML. Blood 83: 3068-3076.
7. Kohn, D. B., et al. (1995). Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat. Med. 1: 1017-1023.
8. Bordignon, C., et al. (1995). Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 270: 470-475.
9. Dunbar, C., et al. (1995). Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 85: 3048-3057.
10. Malech, H. L., et al. (1997). Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc. Natl. Acad. Sci. USA 94: 12133-12138.
11. + cells for six hours without growth factors or on autologous stroma does not improve marking efficiency assessed in vivo. Blood 89: 4040-4046.
12. Hesdorffer, C., et al. (1998). Phase I clinical trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J. Clin. Oncol. 16: 165-172.
13. Hanania, E. G., et al. (1996). Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. Proc. Natl. Acad. Sci. USA 93: 15346-15351.
14. Moscow, J. A., et al. (1999). Engraftment of MDR1 and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy. Blood 94: 52-61.
15. Cowan, K. H., et al. (1999). Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients. Clin. Cancer Res. 5: 1619-1628.
16. von Kalle, C., et al. (1994). Increased gene transfer into human hematopoietic progenitor cells by extended in vitro exposure to a pseudotyped retroviral vector. Blood 84: 2890-2897.
17. Bunnell, B. A., Muul, L. M., Donahue, R. E., Blaese, R. M., and Morgan, R. A. (1995). High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes. Proc. Natl. Acad. Sci. USA 92: 7739-7743.
18. Bauer, T. R., Jr., Miller, A. D., and Hickstein, D. D. (1995). Improved transfer of the leukocyte integrin CD18 subunit into hematopoietic cell lines by using retroviral vectors having a gibbon ape leukemia virus envelope. Blood 86: 2379-2387.
19. Kiem, H. P., et al. (1997). Gene transfer into marrow repopulating cells: Comparison between amphotropic and gibbon ape leukemia virus pseudotyped retroviral vectors in a competitive repopulation assay in baboons. Blood 90: 4638-4645.
20. lo human bone marrow cells reselected after long-term exposure to GALV-pseudotyped retroviral vector. Hum. Gene Ther. 8: 2079-2086.
21. + cells. Hum. Gene Ther. 8: 1685-1694.
22. Movassagh, M., et al. (1998). High-level gene transfer to cord blood progenitors using gibbon ape leukemia virus pseudotype retroviral vectors and an improved clinically applicable protocol. Hum. Gene Ther. 9: 225-234.
23. Moritz, T., Patel, V. P., and Williams, D. A. (1994). Bone marrow extracellular matrix molecules improve gene transfer into human hematopoietic cells via retroviral vectors. J. Clin. Invest. 93: 1451-1457.
24. Moritz, T., et al. (1996). Fibronectin improves transduction of reconstituting hematopoietic stem cells by retroviral vectors: Evidence for direct viral binding to chymotryptic carboxy-terminal fragments. Blood 88: 855-862.
25. Hanenberg, H., Xiao, X. L., Dilloo, D., Hashinao, K., and Williams, D. A. (1996). Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat. Med. 2: 876-882.
26. Kotani, H., et al. (1994). Improved methods of retroviral vector transduction and production for gene therapy. Hum. Gene Ther. 5: 19-28.
27. Lyman, S. D., et al. (1994). Cloning of the human homologue of the murine flt3 ligand: A growth factor for early hematopoietic progenitor cells. Blood 83: 2795-2801.
28. + hematopoietic progenitor cells. Blood 86: 3413-3420.
29. + progenitors to sustain long-term hematopoiesis in immune-deficient mice after ex vivo retroviral-mediated transduction. Blood 89: 446-456.
30. - cells and maintains progenitor cells in vitro. Blood 87: 3563-3570.
31. + bone marrow progenitor cells in vitro. Blood 87: 1317-1325.
32. Zandstra, P. W., Conneally, E., Petzer, A. L., Piret, J. M., and Eaves, C. J. (1997). Cytokine manipulation of primitive human hematopoietic cell self-renewal. Proc. Natl. Acad. Sci. USA 94: 4698-4703.
33. + progenitor cells from single CD34+Thy-1+Lin- primitive progenitor cells. Blood 88: 1619-1631.
34. -) human hematopoietic cells: Novel responses to Flt3-ligand and thrombopoietin. J. Exp. Med. 183: 2551-2558.
35. + human blood cells. Stem Cells 15: 347-352.
36. Piacibello, W., et al. (1997). Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood. Blood 8: 2644-2653.
37. Gottesman, M. M., and Pastan, I. (1993). Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62: 385-427.
38. Chaudhary, P. M., and Roninson, I. B. (1991). Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66: 85-94.
39. Sorrentino, B. P., Brandt, S. J., Gottesman, M., Pastan, I., Cline, A., and Nienhuis, A. W. (1992). Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of the human MDR1. Science 257: 99-103.
40. Boesen, J. J. B., Nooter, K., and Valerio, D. (1994). Circumvention of chemotherapy-induced myelosuppression by transfer of the mdr1 gene. Biotherapy 6: 291-302.
41. Aran, J. M., Pastan, I., and Gottesman, M. M. (1999). Therapeutic strategies involving the multidrug resistance phenotype: The MDR1 gene as target, chemoprotectant, and selectable marker in gene therapy. Adv. Pharmacol. 46: 1-42.
42. Abonour, R., et al. (2000). Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells. Nat. Med. 6: 652-658
43. Baum, C., Hegewisch-Becker, S., Eckert, H. G., Stocking, C., and Ostertag, W. (1995). Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells. J. Virol. 69: 7541-7547.
44. Eckert, H. G., et al. (1996). High-dose multidrug resistance in primary human hematopoietic progenitor cells transduced with optimized retroviral vectors. Blood 88: 3407-3415.
45. Hildinger, M., Eckert, H.-G., Schilz, A. J., John, J., Ostertag, W., and Baum, C. (1998). FMEV vectors: Both retroviral long terminal repeat and leader are important for high expression in transduced hematopoietic cells. Hum. Gene Ther. 5: 1575-1579.
46. Hildinger, M., et al. (1999). Bicistronic retroviral vectors for combining myeloprotection with cell-surface marking. Gene Ther. 6: 1222-1230.
47. Schiedlmeier, B., Kuhlcke, K., Eckert, H. G., Baum, C., Zeller, W. J., and Fruehauf, S. (2000). Quantitative assessment of retroviral transfer of the human multidrug resistance 1 gene to human mobilized peripheral blood progenitor cells engrafted in nonobese diabetic/severe combined immunodeficient mice. Blood 95: 1237-1248.
48. Baum, C., et al. (1996). Improved vectors for hematopoietic stem cell protection and in vivo selection. J. Hematother. 5: 323-329.
49. Shultz, L. D., et al. (1995). Multiple defects in innate and adaptive immunologic function in NOD/LtSz-Scid mice. J. Immunol. 154: 180-191.
50. Larochelle, A., et al. (1996). Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: Implications for gene therapy. Nat. Med. 2: 1329-1337.
51. Cashman, J. D., et al. (1997). Kinetic evidence of regeneration of multilineage hematopoiesis from primitive cells in normal human bone marrow transplanted into immune-deficient mice. Blood 89: 4307-4316.
52. Bhatia, M., Wang, J. C. Y., Kapp, U., Bonnet, D., and Dick, J. E. (1997). Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc. Natl. Acad. Sci. USA 94: 5320-5325.
53. Wang, J. C. Y., Doedens, M., and Dick, J. E. (1997). Primitive human hematopoietic cells are enriched in cord blood compared with adult bone marrow or mobilized peripheral blood as measured by the quantitative in vivo SCID-repopulating cell assay. Blood 89: 3919-3924.
54. Gan, O. I., Murdoch, B., Larochelle, A., and Dick, J. E. (1997). Differential maintenance of primitive human SCID-repopulating cells, clonogenic progenitors, and long-term culture-initiating cells after incubation on human bone marrow stromal cells. Blood 90: 641-650.
55. +-enriched cells from umbilical cord blood in NOD/Ltz-scid/scid mice. Blood 90: 85-96.
56. Conneally, E., Cashman, J., Petzer, A., and Eaves, C. (1997). Expansion in vitro of transplantable human cord blood stem cells demonstrated using a quantitative assay of their lympho-myeloid repopulating activity in nonobese diabetic scid/scid mice. Proc. Natl. Acad. Sci. USA 94: 9836-9841.
57. Van der Loo, J. C. M., Hanenberg, H., Cooper, R. J., Luo, F. Y., Lazaridis, E. N., and Williams, D. A. (1998). Nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mouse as a model system to study the engraftment and mobilization of human peripheral stem cells. Blood 92: 2556-2570.
58. van Hennik, P. B., de Koning, A. E., and Ploemacher, R. E. (1999). Seeding efficiency of primitive human hematopoietic cells in nonobese diabetic/severe combined immune deficiency mice: Implications for stem cell frequency assessment. Blood 34: 3055-3061.
59. Fruehauf, S., et al. (1996). Frequency analysis of multidrug resistance-1 gene transfer into human primitive hematopoietic progenitor cells using the cobblestone area-forming cell assay and detection of vector-mediated P-glycoprotein expression by rhodamine-123. Hum. Gene Ther. 7: 1219-1231.
60. Schilz, A. J., et al. (1998). High efficiency gene transfer to human hematopoietic SCID-repopulating cells under serum-free conditions. Blood 92: 3163-3171.
61. Cavazzana-Calvo, M., et al. (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288: 669-672.
62. + stem cells using RetroNectin coated X-Fold gas permeable bags applied to treatment of X-linked chronic granulomatous disease (X-CGD) [Abstract]. Mol. Ther. 5: S101-S102.
63. Malech, H. I., et al. (2000). Multiple cycles of ex vivo gene therapy for X-linked chronic granulomatous disease (CGD) sustain production of oxidase-normal peripheral blood neutrophils [Abstract]. Mol. Ther. 5: S146.
64. Conneally, E., Eaves, C. J., and Humphries, R. K. (1998). Efficient retroviral-mediated gene transfer to human cord blood stem cells with in vivo repopulating potential. Blood 91: 3487-3493.
65. Marandin, A., et al. (1998). Retrovirus-mediated gene transfer into human CD34+38 low primitive cells capable of reconstituting long-term cultures in vitro and nonobese diabetic-severe combined immunodeficiency mice in vivo. Hum. Gene Ther. 9: 1497-1511.
66. Van Hennik, P. B., et al. (1998). Highly efficient transduction of the green fluorescent protein in human umbilical cord blood stem cells capable of cobblestone formation in long-term cultures and multilineage engraftment of immunodeficient mice. Blood 92: 4013-4022.
67. Barquinero, J., et al. (2000). Efficient transduction of human hematopoietic repopulating cells generating stable engraftment of transgene-expressing cells in NOD/SCID mice. Blood 95: 3085-3093.
68. Sorrentino, B. P., McDonagh, K. T., Woods, D., and Orlic, D. (1995). Expression of retroviral vectors containing the human multidrug resistance 1 cDNA in hematopoietic cells of transplanted mice. Blood 86: 491-501.
69. Zaboikin, M. M., and Schuening, F. G. (1998). Poor expression of MDR1 transgene in HeLa cells by bicistronic Moloney murine leukemia virus-based vector. Hum. Gene Ther. 9: 2263-2275.
70. Goodell, M. A., et al. (1997). Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat. Med. 3: 1337-1345.
71. Challita, P.-M., and Kohn, D. B. (1994). Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo. Proc. Natl. Acad. Sci. USA 91: 2567-2571.
72. Lund, A. H., Duch, M., and Pedersen, F. S. (1996). Transcriptional silencing of retroviral vectors. J. Biomed. Sci. 3: 365-378.
73. Osborne, C. S., Pasceri, P., Singal, R., Sukonnik, T., Cinder, G. D., and Ellis, J. (1999). Amelioration of retroviral vector silencing in locus control region beta-globin-transgenic mice and transduced F9 embryonic cells. J. Virol. 73: 5490-5496.
74. Zentilin, L., Qin, G., Tafuro, S., Dinauer, M. C., Baum, C., and Giacca, M. (2000). Variegation of retroviral vector gene expression in myeloid cells. Gene Ther. 7: 153-166.
75. Bunting, K. D., Galipeau, J., Topham, D., Benaim, E., and Sorrentino, B. P. (1998). Transduction of murine bone marrow cells with an MDR1 vector enables ex vivo stem cell expansion, but these expanded grafts cause a myeloproliferative syndrome in transplanted mice. Blood 92: 2269-2279.
76. Dunbar, C., et al. (2000). Transplantation of rhesus hematopoietic cells with an MDR1 vector does not result in ex vivo or in vivo expansion or a myeloproliferative syndrome. Mol. Ther. 5: 31-32.
77. Mickisch, G. H., Licht, T., Merlino, G. T., Gottesman, M. M., and Pastan, I. (1991). Chemotherapy and chemosensitization of transgenic mice which express the human multidrug resistance gene in bone marrow: Efficacy, potency, and toxicity. Cancer Res. 51: 5417-5424.